André Veillette

André Veillette

Auto-generated profile, based on publicly available information

André Veillette

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Canada

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Trends in Immunology
Verified
Journal Article
Closed access
AVAndré Veillette
André Veillette
JCJun Chen
Jun Chen

19 April 2017 in Nature
Verified
Journal Article
Open access
PDF file
JCJun Chen
Jun Chen
MZMing-Chao Zhong
Ming-Chao Zhong
HGHuaijian Guo
Huaijian Guo
DDDominique Davidson
Dominique Davidson
SMSabrin Mishel
Sabrin Mishel
AVAndré Veillette
André Veillette
The identification of homotypic SLAMF7 interactions responsible for haematopoietic tumour cell phagocytosis by macrophages when the inhibitory receptor/ligand interaction of SIRPα/CD47 is blocked therapeutically. Phagocytosis of tumour cells has a critical role in cancer control, but the pro-phagocytic receptors responsible for this process are largely unknown. André Veillette and colleagues identify homotypic SLAMF7 interactions that are responsible for phagocytosis of haematopoietic tumour cells by macrophages when the inhibitory receptor–ligand interaction of CD47–SIRPα is blocked therapeutically. The authors suggest that the presence of SLAMF7 receptors on haematopoietic tumours could therefore be an important factor in blockade therapy. Cancer cells elude anti-tumour immunity through multiple mechanisms, including upregulated expression of ligands for inhibitory immune checkpoint receptors1,2. Phagocytosis by macrophages plays a critical role in cancer control3,4,5,6. Therapeutic blockade of signal regulatory protein (SIRP)-α, an inhibitory receptor on macrophages, or of its ligand CD47 expressed on tumour cells, improves tumour cell elimination in vitro and in vivo7,8,9,10, suggesting that blockade of the SIRPα–CD47 checkpoint could be useful in treating human cancer11,12,13,14. However, the pro-phagocytic receptor(s) responsible for tumour cell phagocytosis is(are) largely unknown. Here we find that macrophages are much more efficient at phagocytosis of haematopoietic tumour cells, compared with non-haematopoietic tumour cells, in response to SIRPα–CD47 blockade. Using a mouse lacking the signalling lymphocytic activation molecule (SLAM) family of homotypic haematopoietic cell-specific receptors, we determined that phagocytosis of haematopoietic tumour cells during SIRPα–CD47 blockade was strictly dependent on SLAM family receptors in vitro and in vivo. In both mouse and human cells, this function required a single SLAM family member, SLAMF7 (also known as CRACC, CS1, CD319), expressed on macrophages and tumour cell targets. In contrast to most SLAM receptor functions15,16,17, SLAMF7-mediated phagocytosis was independent of signalling lymphocyte activation molecule-associated protein (SAP) adaptors. Instead, it depended on the ability of SLAMF7 to interact with integrin Mac-1 (refs 18, 19, 20) and utilize signals involving immunoreceptor tyrosine-based activation motifs21,22. These findings elucidate the mechanism by which macrophages engulf and destroy haematopoietic tumour cells. They also reveal a novel SAP adaptor-independent function for a SLAM receptor. Lastly, they suggest that patients with tumours expressing SLAMF7 are more likely to respond to SIRPα–CD47 blockade therapy.

1 April 2002 in Annual Review of Immunology
Verified
Journal Article
Closed access
AVAndré Veillette
André Veillette
SLSylvain Latour
Sylvain Latour
DDDominique Davidson
Dominique Davidson
Immune cells are activated as a result of productive interactions between ligands and various receptors known as immunoreceptors. These receptors function by recruiting cytoplasmic protein tyrosine kinases, which trigger a unique phosphorylation signal leading to cell activation. In the recent past, there has been increasing interest in elucidating the processes involved in the negative regulation of immunoreceptor-mediated signal transduction. Evidence is accumulating that immunoreceptor signaling is inhibited by complex and highly regulated mechanisms that involve receptors, protein tyrosine kinases, protein tyrosine phosphatases, lipid phosphatases, ubiquitin ligases, and inhibitory adaptor molecules. Genetic evidence indicates that this inhibitory machinery is crucial for normal immune cell homeostasis.

1 January 2006 in Nature Reviews Immunology
Verified
Journal Article
Closed access
AVAndré Veillette
André Veillette

27 March 2003 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
DDDominique Davidson
Dominique Davidson
MBMarcin Bakinowski
Marcin Bakinowski
MTMatthew L. Thomas
Matthew L. Thomas
VHVaclav Horejsi
Vaclav Horejsi
AVAndré Veillette
André Veillette
PAG/Cbp (hereafter named PAG) is a transmembrane adaptor molecule found in lipid rafts. In resting human T cells, PAG is tyrosine phosphorylated and associated with Csk, an inhibitor of Src-related protein tyrosine kinases. These modifications are rapidly lost in response to T-cell receptor (TCR) stimulation. Overexpression of PAG was reported to inhibit TCR-mediated responses in Jurkat T cells. Herein, we have examined the physiological relevance and the mechanism of PAG-mediated inhibition in T cells. Our studies showed that PAG tyrosine phosphorylation and association with Csk are suppressed in response to activation of normal mouse T cells. By expressing wild-type and phosphorylation-defective (dominant-negative) PAG polypeptides in these cells, we found that the inhibitory effect of PAG is dependent on its capacity to be tyrosine phosphorylated and to associate with Csk. PAG-mediated inhibition was accompanied by a repression of proximal TCR signaling and was rescued by expression of a constitutively activated Src-related kinase, implying that it is due to an inactivation of Src kinases by PAG-associated Csk. We also attempted to identify the protein tyrosine phosphatases (PTPs) responsible for dephosphorylating PAG in T cells. Through cell fractionation studies and analyses of genetically modified mice, we established that PTPs such as PEP and SHP-1 are unlikely to be involved in the dephosphorylation of PAG in T cells. However, the transmembrane PTP CD45 seems to play an important role in this process. Taken together, these data provide firm evidence that PAG is a bona fide negative regulator of T-cell activation as a result of its capacity to recruit Csk. They also suggest that the inhibitory function of PAG in T cells is suppressed by CD45. Lastly, they support the idea that dephosphorylation of proteins on tyrosine residues is critical for the initiation of T-cell activation.

17 February 2010 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Closed access
PDF file
AVAndré Veillette
André Veillette
The signaling lymphocytic activation molecule (SLAM) family of receptors and the SLAM-associated protein (SAP) family of intracellular adaptors are expressed in immune cells. By way of their cytoplasmic domain, SLAM-related receptors physically associate with SAP-related adaptors. Evidence is accumulating that the SLAM and SAP families play crucial roles in multiple immune cell types. Moreover, the prototype of the SAP family, that is SAP, is mutated in a human immunodeficiency, X-linked lymphoproliferative (XLP) disease. In the presence of SAP-family adaptors, the SLAM family usually mediates stimulatory signals that promote immune cell activation or differentiation. In the absence of SAP-family adaptors, though, the SLAM family undergoes a “switch-of-function,” thereby mediating inhibitory signals that suppress immune cell functions. The molecular basis and significance of this mechanism are discussed herein.